The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus

Inclusion Criteria: 1. T2DM 2. 7.0% ≤ HbA1c ≤ 11.0% at screening 3. FPG ≤13.8 mmol/L 4. 19 kg/m2 \< BMI \<35.0 kg/m2 at screening 5. All subjects provided written informed consent before participation Exclusion Criteria: 1. T1DM 2. Patients treated previously with Exenatide or GLP-1 similar 3. At screening visit alanine aminotransferase (ALT) or alkaline phosphatase (AST) more than 2.5 ULN 4. At screening visit estimated glomerular filtration rate (eGFR) ≤ 60 mL/min or Triglyceride(TG)≥ 5 mmol/L 5. Pancreatitis, cholecystitis, gallstones and other gastrointestinal diseases 6. Within the last 12 months prior to screening visit: history of stroke, myocardial infarction, unstable angina, or heart failure requiring hospitalization. Planned coronary, carotid or peripheral artery revascularisation procedures to be performed during the study period 7. History of digestive diseases (e.g.pancreatitis, cholecystitis or gallstones) 8. Patients with severe renal impairment or end-stage renal disease 9. Uncontrolled or inadequately controlled hypertension (systolic blood pressure above 180 mmHg or diastolic blood pressure above 110 mmHg) at screening visit. 10. Use of weight loss drugs within 3 months prior to screening visit 11. Have been treated with exogenous insulin, α-glucosidase, corticosteroid, DPP-4 inhibitor or pramlintide acetate within the 3 months prior to screening. 12. Severe gastrointestinal disease (e.g., gastroparesis) 13. Pregnancy or lactation, women of childbearing potential with no effective contraceptive method 14. Participant who participated in any drug clinical trial within the last 3 months prior to screening visit 15. History of severe hypersensitivity to rExenatide-4 or any product components